4Tissue

Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.

Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology with best-in-class therapeutics.

neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam.

Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo.

Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical needs that have not been met. The company uses its unique CONFO® technology to stabilize the functional shapes of GPCRs, providing a strong foundation for drug discovery. By stabilizing the active state conformations of these receptors, Confo Therapeutics is able to uncover important structural details that were previously unknown, leading to the development of new agonists for improved therapeutic treatments.

Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock. Through a combination of advanced research, animal science, and biotech, Animab produces products that enhance animal health, decrease expenses, and promote sustainability. Specifically, Animab offers a safe and sustainable solution for safeguarding the intestinal health of piglets after weaning. The antibodies in Animab mimic secretory IgA, a natural antibody passed on through colostrum and milk to safeguard nursing animals.

Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations of selective HDAC6 inhibitors that can be used to treat axonopathies like Charcot Marie Tooth disease. These new compounds show promise in protecting against nerve degeneration and aiding in the repair of peripheral myelin and axons.

Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding specific molecules to AAV vectors, the company is able to develop more precise and safer gene therapies, a major breakthrough in the industry. Established as a spin-off from KU Leuven and Trellis, Tavira is utilizing cutting-edge research to enhance gene therapy through modular AAV capsid technologies.

AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic monoclonal immunizer particles ("agomAbs") animate atomic and cell fix systems that can possibly reestablish organ capability in patients with fibrotic, fiery, immune system and degenerative illnesses.

BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.

Hedera-22 broadened its focus to incorporate the discovery of natural products using internal bioinformatics prediction technologies.